文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

限制性液体管理联合早期降阶梯与常规治疗在危重症患者中的比较(reduce试验):一项可行性随机对照试验

Restrictive fluid management with early de-escalation versus usual care in critically ill patients (reduce trial): a feasibility randomized controlled trial.
PubMed 文献 · Crit Care · 2025-09-25
一句话结论在初始液体复苏后的休克患者中,限制性液体策略联合早期降阶梯可行,第3天液体平衡更低且可能缩短住院时间,未增加不良事件。

本研究为单中心可行性随机对照试验,纳入内科ICU需液体复苏的休克患者100例,1:1随机分为限制性液体策略组与常规治疗组。限制性组目标为3天内接近零液体平衡,通过限制液体入量并在需要时使用利尿剂或机械性液体清除实现。主要终点第3天累积液体平衡在限制性组显著低于常规组(‒2353 mL vs 793 mL,p<0.001),第7天趋势持续(‒3032 mL vs 1125 mL,p<0.001)。限制性组ICU住院时间和总住院时间更短(7 vs 10天,p=0.006;16 vs 22天,p=0.02),院内死亡率和30天死亡率两组无统计学显著差异(18% vs 38%,p=0.05;12% vs 30%,p=0.05),急性肾损伤和肾脏替代治疗使用无显著差异。结论认为该策略可行,可能减少液体蓄积并显示出缩短住院时间的信号,未增加不良事件。

要点

  • 初始液体复苏后,限制性组通过限制入量及必要时利尿或机械清除,第3天累积液体平衡为‒2353 mL,常规组为793 mL(p<0.001)。
  • 限制性组第7天累积液体平衡为‒3032 mL,常规组为1125 mL(p<0.001),液体负平衡趋势持续。
  • 限制性组ICU住院时间7天 vs 常规组10天(p=0.006),总住院时间16天 vs 22天(p=0.02)。
  • 院内死亡率18% vs 38%(p=0.05)、30天死亡率12% vs 30%(p=0.05),两组无统计学显著差异。
  • 急性肾损伤发生率及肾脏替代治疗使用两组无显著差异,限制性策略未增加不良事件。

适用人群与场景

  • 纳入内科ICU中需要液体复苏的休克患者,在初始液体复苏后随机分组。
  • 研究为单中心可行性随机对照试验,样本量100例。

处置流程与药物剂量

  • 限制性液体策略组目标为3天内接近零液体平衡,通过限制液体入量实现。
  • 限制性组在需要时使用利尿剂或机械性液体清除以达到目标。
  • 对照组接受常规治疗。

研究设计与关键结果

  • 单中心可行性随机对照试验,纳入100例休克患者,1:1随机分为限制性液体策略组(50例)与常规治疗组(50例)。
  • 主要终点第3天累积液体平衡:限制性组‒2353 mL vs 常规组793 mL(p<0.001)。
  • 第7天累积液体平衡:限制性组‒3032 mL vs 常规组1125 mL(p<0.001)。
  • ICU住院时间:限制性组7天 vs 常规组10天(p=0.006);总住院时间:限制性组16天 vs 常规组22天(p=0.02)。
  • 院内死亡率:限制性组18% vs 常规组38%(p=0.05);30天死亡率:限制性组12% vs 常规组30%(p=0.05),均无统计学显著差异。
  • 急性肾损伤发生率及肾脏替代治疗使用两组无显著差异。

证据类型、等级与局限

  • 证据类型:单中心可行性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在急性液体复苏后的危重症患者中,限制性液体策略联合早期降阶梯和去复苏是可行的,可能减少液体蓄积,并显示出缩短住院时间的信号,未增加不良事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Optimal fluid management in critically ill patients varies across different phases of care. This study examined the feasibility of adding a restrictive fluid strategy with early de-escalation to standard care for patients with circulatory shock.

METHODS: We performed a single-center, feasibility, randomized controlled trial, involving patients with shock who required fluid resuscitation and were admitted in the medical intensive care unit. After initial fluid resuscitation, patients were randomly assigned (1:1) to either a restrictive fluid strategy or usual care. The restrictive group targeted a near-zero fluid balance over 3 days by limiting fluid intake and using diuretics or mechanical fluid removal when needed. The primary outcome was cumulative fluid balance at day 3. The secondary outcomes were the lengths of stay in the intensive care unit and the hospital, the mechanical ventilation duration, acute kidney injury, renal replacement therapy, and mortality.

RESULTS: We enrolled 100 patients, assigning 50 to the restrictive strategy and 50 to usual care. By day 3, the restrictive group showed a lower cumulative fluid balance than usual care (‒2353 mL vs. 793 mL, p < 0.001). This trend continued to day 7 (‒3032 mL vs. 1125 mL, p < 0.001). The restrictive group also had shorter stays in the intensive care unit and the hospital (7 vs. 10 days, p = 0.006; 16 vs. 22 days, p = 0.02). There were no statistically significant differences in hospital or 30-day mortality rates between the groups (18% vs. 38%, p = 0.05; 12% vs. 30%, p = 0.05, respectively). Similarly, no significant differences were observed in the incidence of acute kidney injury or the use of renal replacement therapy.

CONCLUSIONS: A restrictive fluid strategy with early de-escalation and de-resuscitation is feasible and may reduce fluid accumulation and showed a signal for reduced hospital stay without increasing adverse events in critically ill patients following acute fluid resuscitation.

TRIAL REGISTRATION: TCTR20220719002 (The trial has been reviewed and approved by TCTR committee on July 16th, 2022).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Naorungroj T, Prajantasen U, Sanla-Ead T, et al. Restrictive fluid management with early de-escalation versus usual care in critically ill patients (reduce trial): a feasibility randomized controlled trial. Crit Care. 2025. PMID: 40999428. doi:10.1186/s13054-025-05624-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。